Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd. (NASDAQ: ENTX) generates a steady flow of news as a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. News coverage on this page focuses on the company’s progress with its proprietary N-Tab™ oral peptide platform and its pipeline of tablet-based biologic candidates.
Investors and followers of ENTX can use this news feed to track key developments around EB613, Entera Bio’s lead oral PTH(1-34) (teriparatide) osteoanabolic tablet for postmenopausal women with osteoporosis or low bone mineral density. Updates often include Phase 2 clinical data, post-hoc analyses of bone mineral density outcomes, presentations at bone and endocrine conferences, and regulatory milestones such as FDA alignment on Phase 3 trial design and acceptance of total hip BMD as a primary endpoint.
The news stream also highlights progress in the EB612 program for hypoparathyroidism, including preclinical pharmacokinetic and pharmacodynamic data for a proprietary long-acting PTH analog formulated as a once-daily oral tablet. Coverage extends to Entera Bio’s collaboration with OPKO Health on oral GLP-2 and oxyntomodulin tablet candidates, with reports on preclinical data for short bowel syndrome and obesity programs presented at international nutrition and endocrine meetings.
In addition, readers will find quarterly financial results, business updates, participation in healthcare and investor conferences, and commentary from company leadership on strategy and clinical priorities. This page brings together ENTX press releases and related announcements so that investors, clinicians and other stakeholders can follow the company’s clinical, regulatory and collaboration milestones in one place.
Entera Bio Ltd. (NASDAQ: ENTX) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Spiros Jamas will present an overview of the company’s business during this virtual event. A webcast of the presentation will be available on Entera's website starting March 9 at 7 a.m. ET. Entera is focused on developing orally delivered large molecule therapeutics, with key products like EB613 and EB612 in Phase 2 clinical development.
Entera Bio Ltd. (NASDAQ: ENTX) announced the publication of its Phase 2a study results for EB612 in the Journal of Bone and Mineral Research. The study demonstrated a 42% reduction in calcium supplement use (p=0.001) among patients with hypoparathyroidism. Significant improvements included maintenance of serum calcium levels, a 23% decrease in serum phosphate (p=0.0003), and a 5% increase in quality of life scores (p=0.03). The trial involved 19 patients, with 17 completing it without serious adverse events. Entera plans to enhance EB612 formulations and start a new trial in 2022.
Entera Bio Ltd. (NASDAQ: ENTX) has initiated a research program to develop an oral GLP-2 analog using its proprietary platform technology. This move aims to provide an alternative to the current injectable treatment for short bowel syndrome, teduglutide, which generated $574 million in sales in 2019. The company believes GLP-2 analogs could address various metabolic diseases, enhancing patient compliance and reducing costs. Entera's technology has significant potential in the oral delivery of large molecules, aligning with a growing market for biologics valued at $20 billion annually.
Entera Bio Ltd. (NASDAQ: ENTX) announced a Letter to Shareholders from newly appointed CEO Spiros Jamas, emphasizing the company's progress in developing orally delivered therapeutics. They bolstered their balance sheet with $8.6 million in cash, funding clinical programs into Q3 2021. Key highlights include FDA approval for their oral osteoporosis drug, EB613, and positive interim data from clinical trials. The potential market for EB613 is projected to grow to $20 billion if successful. The company also reported positive results for EB612, an oral treatment for hypoparathyroidism, meeting all trial endpoints.
Entera Bio Ltd. (NASDAQ: ENTX) has received FDA approval to proceed with the initial U.S. clinical trial for EB613, an orally delivered human parathyroid hormone (1-34) aimed at treating osteoporosis. This positions EB613 as a pioneering once-daily oral treatment for osteoporosis patients. The ongoing Phase 2 trial's biomarker data is expected in Q1 2021, with final bone mineral density results anticipated in Q2 2021. The company aims for a pivotal Phase 3 trial post-analysis, highlighting the unmet need for oral PTH therapies.
Entera Bio Ltd. (NASDAQ: ENTX) has appointed Spiros Jamas as its new CEO effective January 4, 2021, succeeding interim CEO Dr. Roger Garceau. Dr. Jamas brings over 30 years of biopharmaceutical experience, aiming to advance Entera’s osteoporosis treatment EB613 and hypoparathyroidism treatment EB612, both in Phase 2 trials. The company anticipates key data readouts in the first half of 2021, presenting potential growth opportunities. Shareholder approval is required for Dr. Jamas' engagement terms.
Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial of EB613, aimed at treating osteoporosis. A total of 161 subjects were randomized, with interim data showing a 2.15% mean increase in lumbar spine bone mineral density (BMD) compared to placebo. The company plans to report additional biomarker data in Q1 and Q2 of 2021. Financially, Entera reported revenues of $144,000 for the nine months ended September 30, 2020, alongside an operating loss of $(8.8) million and a net loss of $(7.7) million. Cash reserves stood at $7.1 million as of September 30, 2020.
Entera Bio Ltd. (NASDAQ: ENTX) will release its business and financial results for Q3 2020 on November 19, 2020, before U.S. markets open. The management team will host a conference call at 8:30 a.m. ET on that day to discuss the results, with a Q&A session to follow. Participants can join the call by dialing (855) 547-3865 within the U.S. or (409) 217-8787 internationally, using the conference ID 9495026. A live audio webcast will also be available on Entera's website.
Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial for EB613, an oral treatment for osteoporosis. This study involves 161 postmenopausal women and aims to evaluate the drug's effect on bone mineral density (BMD). Interim results showed a placebo-adjusted BMD increase of 2.15% in the highest dose group. Full biomarker data is expected in Q1 2021, with final results due in Q2 2021. Entera has $7.1 million in cash, sufficient to support operations into the second quarter of 2021, despite challenges from COVID-19.
Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C. Wainwright Annual Israel Conference on November 12, 2020 at 8:00 a.m. ET. The event will showcase its advancements in orally delivered large molecule therapeutics, targeting unmet medical needs in healthcare.
Entera’s proprietary technology addresses challenges in drug absorption, focusing on its lead candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in Phase 2 clinical development.